Autophagy modulation attenuates sorafenib resistance in HCC induced in rats. [PDF]
Cell Death Dis, 2023 Hepatocellular carcinoma (HCC) has risen as the villain of cancer-related death globally, with a usual cruel forecasting. Sorafenib was officially approved by the FDA as first-line treatment for advanced HCC.
Elleithi Y, El-Gayar A, Amin MN.
europepmc +5 more sources
Mechanism of sorafenib resistance associated with ferroptosis in HCC
Frontiers in Pharmacology, 2023 Hepatocellular carcinoma (HCC) is the most familiar primary hepatic malignancy with a poor prognosis. The incidence of HCC and the associated deaths have risen in recent decades.
Lingling Guo +3 more
doaj +4 more sources
Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma
Computational and Structural Biotechnology Journal, 2023 As sorafenib is a first-line drug for treating advanced hepatocellular carcinoma, sorafenib resistance has historically attracted attention. However, most of this attention has been focused on a series of mechanisms related to drug resistance arising ...
Ruiqi Zheng +11 more
doaj +4 more sources
Signal Transduction and Targeted Therapy, 2021 The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still facing critical challenges. The first targeted therapy, sorafenib, prolonged the overall survival by months.
Junhao Zheng, Yifan Wang, Xiao Liang
exaly +3 more sources
Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC. [PDF]
Mol CancerSorafenib is a major nonsurgical option for patients with advanced hepatocellular carcinoma (HCC); however, its clinical efficacy is largely undermined by the acquisition of resistance. The aim of this study was to identify the key lncRNA involved in the
Chan YT +11 more
europepmc +5 more sources
Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression [PDF]
Infectious Agents and Cancer, 2021 Background HBV promotes cell survival by upregulating the expression of the cellular inhibitor of apoptosis protein 2 (cIAP2), however whether it is involved in HBV-induced sorafenib resistance in liver cancer remains unclear.
Shouhua Zhang +9 more
doaj +2 more sources
Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2 [PDF]
Biology, 2023 Sorafenib, a kinase inhibitor, has shown promising therapeutic efficacy in a subset of patients with acute myeloid leukemia (AML). However, despite its clinical effectiveness, sorafenib resistance is frequently observed in clinical settings, and the ...
Xi Xu +7 more
doaj +2 more sources
Microvesicles: the functional mediators in sorafenib resistance
Cancer Drug Resistance, 2022 Overcoming drug resistance in cancer therapies remains challenging, and the tumor microenvironment plays an important part in it. Microvesicles (MVs) are functional natural carriers of cellular information, participate in intercellular communication, and dynamically regulate the tumor microenvironment. They contribute to drug resistance by transferring
Cong He +4 more
openalex +4 more sources
SMYD2 epigenetically activates BMP4/SMAD1/5/8/ID3 axis to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma [PDF]
Neoplasia: An International Journal for Oncology ResearchBackground: Drug resistance prominently hampers the effects of sorafenib in hepatocellular carcinoma (HCC). Epigenetics play important roles in drug resistance.
Shanshan Wang +7 more
doaj +3 more sources
PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis [PDF]
Cell Death and Disease, 2022 Phosphoglycerate kinase 1 (PGK1) has complicated and multiple functions in cancer occurrence, tumor progression and drug resistance. Sorafenib is the first-line treatment targeted drug for patients with kidney renal clear cell carcinoma (KIRC) as a ...
Yu He +10 more
openalex +2 more sources